-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 11, Zhongsheng Pharmaceutical issued an announcement stating that its wholly-owned subsidiary, Huanan Pharmaceutical, had received the "Notice of Approval of Drug Supplement Application" approved and issued by the State Food and Drug Administration for the treatment of type 2 diabetes
.
Diabetes mellitus is a systemic chronic metabolic disease characterized by hyperglycemia and disorder of sugar, fat and protein metabolism due to absolute or relative shortage of insulin
.
Currently, the World Health Organization (1999) diabetes etiology classification system is used, which is divided into 4 categories, of which type 2 diabetes is the most common type in clinical practice
There are three main types of oral hypoglycemic drugs in clinical use.
Glipizide is a sulfonylurea hypoglycemic agent, which has significantly enhanced selective binding ability with β cells, and triggers hypoglycemia, neutropenia and cardiovascular adverse reactions The rate is low and it is effective for most patients with type 2 diabetes
.
Glipizide tablets are listed in China's National Essential Drug List and National Medical Insurance List
.
According to the chemical drug terminal competition pattern database of Chinese city public hospitals on Mynet, the sales of glipizide tablets from 2018 to 2020 are RMB 222.
